These studies have shown a consistent unexplained statistically significant excess mortality in patients who have anaemia associated with various common cancers who received recombinant human erythropoietin compared to controls.
Need uuringud näitasid omavahel kooskõlas seletamatut statistiliselt olulist suremuse tõusu kasvajast tingitud aneemiaga patsientidel, keda raviti inimese rekombinantse erütropoetiiniga, võrreldes kontrollrühmaga.